The race is on to test an experimental Ebola vaccine as West Africa grapples with an out-of-control outbreak and the U.S. scrambles to rectify breaches in protocol after a patient with the virus died at a Dallas hospital and a healthcare worker tested positive for the infection.
GlaxoSmithKline may be hitting obstacles all over the world, what with bribery fines and probes, Advair rivals in Europe, and the like. But the U.K. drugmaker has managed to make progress on its plan to offload some of its older products.
In its latest move to revive profits and slim down a sagging portfolio, GlaxoSmithKline is planning to put $3 billion worth of older drugs on the chopping block, shedding products by geographical region.
Six months after announcing a series of deals aimed at refocusing its R&D efforts, Novartis is starting to provide some glimpses of what the new company will look like--and who will and will not be leading it.
A debate has raged over the past couple of years over whether world governments are wasting money by stockpiling Roche's Tamiflu and GlaxoSmithKline's Relenza to help combat a potential flu epidemic. At issue is a tough question: Are the drugs effective enough to justify the estimated $2 billion spent to stockpile them?
As the Ebola outbreak continues to ravage Liberia, Guinea and Sierra Leone, GlaxoSmithKline said Phase I trials of its experimental Ebola vaccine are expected to start in West Africa in the next few weeks, and Phase II trials are likely to begin in early 2015.
GlaxoSmithKline has disclosed its second deal in less than a week designed to improve the analysis of genetic mutations in oncology. The latest collaboration is with GE Healthcare to establish a network of clinical laboratories to identify genetic mutations associated with specific tumor types.
GlaxoSmithKline is expanding its efforts to encourage research into bioelectronic medicine, putting up $5 million to support R&D projects around the world.
The European Society for Medical Oncology meeting may not be as enormous as its U.S. counterpart, but plenty of news is flowing. And some of the new data presented in Madrid over the weekend is pretty dramatic.
Over the weekend oncology investigators from all around the world gathered in Madrid at the European Society for Medical Oncology (ESMO) 2014 Congress to review the latest advances--and setbacks--in the fast-moving field of cancer drug research. As usual, the big companies dominated the discussions, as rival oncology groups touted new data as they tried to position competing therapies in the global scramble to develop new and better cancer drugs, now one of the hottest fields in R&D.